Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • The Success of ASAM’s CONTINUUM – Large System Adventures in Innovation (1 CME)

    Product not yet rated Contains 4 Component(s), Medical Credits Offered

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning about ASAM's Criteria from this conference recording from The ASAM 49th Annual Conference (2018).

    (1.0 CME) In this conference recording from the 2018 Annual Conference, you will learn about ASAM's criteria from the foremost experts in the field. 

    The ASAM Criteria decision rules are complex, leading to unauthorized, unvalidated attempts at abridgement. Eventually, the U.S. funded a standardized implementation: CONTINUUM™. Large county/state systems report a rapid learning curve and 60-minute average duration. The 10-minute CO-Triage™ provisionally determines the initial level-of-care referral. Piloting in Massachusetts (N=3,600) found good level-of-care distributions, conformity with ASAM’s principles, and provider/patient acceptance. Successful large system pilots have expanded public sector use in Massachusetts, Los Angeles and California’s prison system. In 2017, Los Angeles County (population: 10.1 million) signed a 10-year contract with ASAM for 1,500 clinicians to routinely use CONTINUUM and CO-Triage. A 25 year-long dream, this progress now demands serious new efforts by ASAM members, leaders and researchers.

    Learning Objectives: 

    • Upon completion, participant will be able to understand the evidence-base underlying the ASAM Criteria CONTINUUM™ system.
    • Upon completion, participant will be able to explain the purpose, clinical and system application of CO-Triage™ and CONTINUUM to decision makers.
    • Upon completion, participant will be able to participate in local and ASAM-wide planning and design enhancement to further the development of the CONTINUUM system.

    David R. Gasfriend

    MD, DFASAM

    "In his 25 years at Harvard Medical School, Dr. Gastfriend directed the Addiction Research Program at Massachusetts General Hospital and founded the MGH-McLean Addiction Psychiatry Fellowship. His research operationalized and validated ASAM’s Criteria, contributing to their endorsement by most U.S. states, the VA and the Department of Defense. These NIDA- and NIAAA-funded studies led to CONTINUUM - the ASAM Criteria Decision Engine(TM), developed with the support of the U.S. Substance Abuse and Mental Health Services Administration for nationwide release.

    From 2004-2013, Dr. Gastfriend was Vice President at Alkermes, Inc., where he supported gaining FDA approval of VIVITROL® for alcohol and opioid dependence and conducted clinical, criminal justice, and health economic research in addiction.
    In 2014-2015 he was CEO of the Treatment Research Institute (TRI), the Philadelphia-based international research and policy center. He continues as Scientific Advisor, providing guidance to its researchers on projects such as the Addiction Severity Index and the Kennedy Foundation Parity Monitoring Project.

    In 2016, he co-founded, with his son, Eric Gastfriend MBA, DynamiCare Health(TM), to provide a nationally scalable, standardized, low-cost smartphone implementation for contingency management and foster wide-scale adoption of this evidence-based approach to incentivizing healthy recovery behaviors.

    NIDA granted him a Mid-Career Investigator Award for Patient-Oriented Research in 2000. In 2007, he received the Boston Business Journal's “Champion in Health Care – Innovator Award”. He is currently Principal Investigator on the $13 million PCORI-funded PATH Study of integrated addiction and primary care. He received ASAM's 2012 McGovern Award and Lecture for contributions to addiction treatment and society. Among his 150 scientific publications are ""The ASAM Criteria"" and ""Addiction Treatment Matching"". He has advised the governments of Belgium, China, Iceland, Israel, Norway, Russia and the U.S. on alcohol and drug addiction treatment. "

    David Mee-Lee

    MD, FASAM

    David Mee-Lee, M.D. is a board-certified psychiatrist, and is certified by the American Board of Addiction Medicine (ABAM). Based in Davis, California, he trains and consults both nationally and internationally.  Dr. Mee-Lee is Chief Editor of the American Society of Addiction Medicine's (ASAM) Criteria for the Treatment of Addictive, Substance-Related, and Co-Occurring Conditions and is President of DML Training and Consulting. He is co-founder of the Institute for Wellness Education. Dr. Mee-Lee has forty years of experience in person centered treatment and program development for people with co-occurring mental health and substance use conditions.

    Paul H. Earley

    MD, DFASAM

    Dr. Earley has worked in Addiction Medicine for over 30 years. He treats all types of addictive disorders and specializes in the assessment, treatment and management of health care professionals. As a therapist, he works with patients already in recovery, providing long term therapy for those who suffer from this disease. His professional expertise extends to advocacy for professionals before agencies and licensing boards. 

    Dr. Earley is a dynamic speaker and educator; he speaks and trains on topics of addiction, its treatment and addiction among health care professionals. In addition, he trains therapists about the neurobiological basis of psychotherapy. In his travels, he has provided training in the United States, Canada, the United Kingdom, Italy, Iceland and Switzerland.

    He is the author of two books and several research articles on addiction and its treatment. His most recent book, RecoveryMind Training is an innovative and comprehensive process designed to reengineer addiction treatment. He is a contributing author to the American Society of Addiction Medicine (ASAM) Textbook: Principles of Addiction Medicine, as author of the chapter: Physician Health Programs and Addiction among Physicians. He is a contributing author to the ASAM Criteria. His work was featured in the documentary series on addiction entitled Close to Home by Bill Moyers.

    Currently, Dr. Earley is the Medical Director of the Georgia Professionals Health Program, Inc., the Physicians Health Program (PHP) for the state of Georgia and the President-elect of the Federation of State Physician Health Programs (FSPHP). Dr. Earley is the current president-elect of the American Society of Addiction Medicine (ASAM). He is a Distinguished Fellow of ASAM and has served on the board of ASAM for over 14 years in several capacities.

    Gary Tsai

    MD, FASAM, FAPA

    Gary Tsai, M.D. is board certified in both general adult psychiatry and addiction medicine, and is the Medical Director and Science Officer of the Substance Abuse Prevention and Control, a division of the Los Angeles County Department of Public Health. In this role, he is responsible for providing clinical leadership to oversee substance use disorder (SUD) research, epidemiology and evaluation, as well as a full spectrum of SUD prevention, treatment, and recovery support services for the 10 million residents of Los Angeles County. He continues clinical practice at Cedars-Sinai Medical Center, and is a member of the Advisory Board of the Treatment Advocacy Center and Partners for StrongMinds, a former APA / SAMHSA Minority Fellow, and is active in the LPS Reform Task Force. 

    Having experienced the stigma and criminalization that often accompanies serious mental illness as the son of a mother with schizophrenia, Dr. Tsai is a passionate advocate for improving our behavioral health systems. In his pursuit of meaningful change, Dr. Tsai is also the founder of Forgotten Films, a film production company focusing on social issue projects, specializing in behavioral health. Its first film, "Voices," premiered on public television in May 2015 for Mental Health Awareness Month and was awarded a 2016 SAMHSA Voice Award, Honorable Mention.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of AMA PRA Category 1 Credit(s)™ for completing this course.

  • National Perspectives Plenary (1 CME)

    Contains 4 Component(s), Medical Credits Offered

    Earn 1 AMA PRA Category 1 Credit(s)™ while listening to this conference recording from innovators shaping the field of addiction medicine at the national level at The ASAM 49th Annual Conference (2018). This session was made available free of charge by ASAM until 11/16/18.

    (1.0 CME) In this conference recording from the 2018 Annual Conference, connect with the innovators shaping the field at the national level. ASAM President Kelly J. Clark, MD, MBA, DFASAM, moderates an informal conversation with representatives from NIAAA, NIDA, and the CDC. The conversation includes questions on emerging issues and advances in addiction medicine, increasing the addiction medicine workforce, and improving the quality of care for patients.

    George F. Koob

    PhD

    George F. Koob, PhD is Director of the National Institute on Alcohol Abuse and Alcoholism of the National Institutes of Health, Washington, DC. As an authority on alcoholism, drug addiction and stress, he has contributed to our understanding of the neurocircuitry associated with the acute reinforcing effects of alcohol and drugs of abuse and the neuroadaptations of the reward and stress circuits associated with the transition to dependence. Dr. Koob has published over 650 peer reviewed papers and several books including the “Neurobiology of Addiction," a comprehensive treatise on emerging research in the field. He has mentored 11 PhD students and over 75 post-doctoral fellows.

    Wilson Compton

    MD, MPE

    Dr. Wilson M. Compton serves as the Deputy Director of the National Institute on Drug Abuse (NIDA) of the National Institutes of Health. In his current role, Dr. Compton's responsibilities include providing scientific leadership in the development, implementation, and management of NIDA's research portfolio and working with the Director to support and conduct research to improve the prevention and treatment of drug abuse and addiction. Prior to his current appointment, Dr. Compton served as the Director of NIDA's Division of Epidemiology, Services and Prevention Research from 2002 until 2013. In this leadership role, he oversaw the scientific direction of a complex public health research program of national and international scope addressing: 1) the extent and spread of drug abuse, 2) how to prevention drug abuse, and 3) how to implement drug abuse prevention and treatment services as effectively as possible. Before joining NIDA, Dr. Compton was Associate Professor of Psychiatry and Director of the Master in Psychiatric Epidemiology Program at Washington University in Saint Louis as well as Medical Director of Addiction Services at the Barnes-Jewish Hospital in Saint Louis. Dr. Compton received his undergraduate education from Amherst College. He attended medical school and completed his residency training in psychiatry at Washington University. During his career, Dr. Compton has achieved multiple scientific accomplishments: he was selected to serve as a member of the DSM-5 Revision Task Force; is the author of more than 130 articles and chapters; and is an invited speaker at multiple high-impact venues. Dr. Compton is the recipient of multiple awards and in 2008, he received the Senior Scholar Health Services Research Award from the American Psychiatric Association, in 2010 the Paul Hoch Award from the American Psychopathological Association, in both 2012 and 2013, he was selected to receive the Leveraging Collaboration Award from the Food and Drug Administration. In 2013, Dr. Compton received the prestigious Health and Human Services Secretary's Award for Meritorious Service.

    Debbie Dowell

    MD, MPH

    Debbie Dowell is Senior Medical Advisor/Chief Medical Officer for the Division of Unintentional Injury Prevention at the Centers for Disease Control and Prevention (CDC), CDR in the US Public Health Service, and was the lead author of the 2016 CDC Guideline for Prescribing Opioids for Chronic Pain. She previously led CDC’s Prescription Drug Overdose Team and served as advisor to New York City’s Health Commissioner. Dr. Dowell completed residency and chief residency in Primary Care Internal Medicine at the NYU School of Medicine, where she later joined the faculty as a clinical assistant professor. Dr. Dowell is Board Certified in Internal Medicine and practiced medicine at a community health center in New York City.

    She has conducted research on quality and safety in medical care, on the effects of clinical guidelines, and on the effectiveness of interventions to prevent opioid overdose, including Prescription Drug Monitoring Programs and academic detailing. She received her BA and MD from Columbia University, her MPH from the Johns Hopkins Bloomberg School of Public Health, and is a graduate of CDC’s Epidemic Intelligence Service (EIS).

    Kelly Clark (Moderator)

    MD, MBA, DFASAM, DFAPA

    Dr. Kelly J. Clark is the President Elect of ASAM. She currently chairs the Public Policy Council, consisting of the Legislative Advocacy, Payer Relations, and Public Policy Committees.

    Board certified in addiction medicine and psychiatry, she has focused her career on issues of prescription drug abuse, evidence informed behavioral health care, and payment reform. Dr. Clark is Chief Medical Officer of CleanSlate Centers, a multi-state medical group currently treating over 5,000 opioid addicted patients with medication management, and which has received a SAMHSA Science to Service Award for Office Based Opioid Treatment. She is active on the Association of Managed Care Pharmacy's Addiction Treatment Advisory Group; served on the writing committee of the Johns Hopkins Bloomberg School of Public Health's recent policy document, “The Prescription Drug Epidemic: An Evidence Based Approach”; and led the workgroup on Health Systems and Reimbursement at SAMHSA's Buprenorphine Summit.

    As the Behavioral Health Medical Director of CDPHP, a non-profit health plan in New York, she provided the clinical leadership for in-sourcing the management of behavioral health benefits. As Chief Medical Officer for Behavioral Health Group, she again focused on opioid addiction. Her expertise in payment models, quality metrics, medical-behavioral health integration, and clinical care delivery systems, as well as her clinical work treating people with addictive disease, all allow her to offer insights and recommendations to address the current epidemic.

    As faculty of the University of Massachusetts Medical School for eight years, Dr. Clark trained students and resident physicians on addiction. She is currently a member of the American Psychiatric Association's Integrated Care Work Group; the National Rx Drug Abuse Summit Advisory Board; and the faculty of the Virginia Tech Carilion School of Medicine.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of AMA PRA Category 1 Credit(s)™ for completing this course.

  • The ASAM Pain & Addiction: Common Threads XIX 2018 (8 CME)

    Contains 10 Product(s)

    Participants will learn clinical best practices and new research developments for treating patients with pain and addiction and how to begin to integrate these techniques into their own practices.

    OVERVIEW
    The ASAM Pain & Addiction: Common Threads Course is one of ASAM’s longest running and most popular courses. This course is designed to develop learners’ clinical skills and improve treatment of patients who fall somewhere in the gray area around pain and addiction. This course is designed for those in the addiction medicine field who already have some experience with pain and addiction.  

    This year’s course will address some of the most common barriers and challenges standing in the way of effective treatment and provide learners with skills or resources to immediately use in their practices. Presenters will address challenges such as appropriately assessing, diagnosing or treating patients (particularly those with psychiatric co-morbidities). Inaccurate diagnosis or referral can hinder treatment progress and impact patient trust in their health care providers. Presenters will also address complex, challenging patient cases such as patients on high doses of opioids or sedatives, patients with nicotine dependence, special patient populations, and many others. Lastly, presenters will review components of strong integrated practice settings and provide resources for learners to use in their own clinical practices. Many presentations will have a non-didactive component allowing participants to either self-reflect, review challenging cases, or engage with the presenters.

    LEARNING OBJECTIVES

    Upon completion, participants should be able to: 
    1. Distinguish between physiological dependence, substance use disorder, misuse, tolerance, and nonadherence in the context of pain.
    2. Use physical exams, functional assessments, screening tools, collateral information, and other tools in a clinical setting.
    3. Describe the interaction between pain, pain medication, addiction, and the patient’s emotional or psychological state. 
    4. Make appropriate treatment decisions for patients with pain, addiction, and psychiatric comorbidities.
    5. Explain the impacts of nicotine on pain treatment and develop methods for addressing nicotine use with patients.
    6. Manage the complex treatment needs of pregnant populations with pain and/or addiction.
    7. Direct or implement the medical management of withdrawal from opioids and other drugs.
    8. Evaluate the recent literature on benefits and limitations medication assisted treatment.
    9. Assess various practice models and create a plan for developing an integrated pain and addiction practice.

    This course is aimed toward addiction medicine specialists who treat patients with chronic pain and/or substance use disorders. Healthcare providers from other specialties who are interested in treating patients with chronic pain and addiction are also encouraged to attend.

    Upon completion, participants should be able to:

    1. Distinguish between physiological dependence, substance use disorder, misuse, tolerance, and nonadherence in the context of pain.
    2. Use physical exams, functional assessments, screening tools, collateral information, and other tools in a clinical setting.
    3. Describe the interaction between pain, pain medication, addiction, and the patient’s emotional or psychological state.
    4. Make appropriate treatment decisions for patients with pain, addiction, and psychiatric comorbidities.
    5. Explain the impacts of nicotine on pain treatment and develop methods for addressing nicotine use with patients.
    6. Manage the complex treatment needs of pregnant populations with pain and/or addiction.
    7. Direct or implement the medical management of withdrawal from opioids and other drugs.
    8. Evaluate the recent literature on benefits and limitations medication assisted treatment.
    9. Assess various practice models and create a plan for developing an integrated pain and addiction practice.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 8 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 8 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of AMA PRA Category 1 Credit(s)™ for completing this course.

  • Move from Good to Great Presentations: Audience Aboard, Not Bored (1.5 CME)

    Contains 4 Component(s), Medical Credits Offered

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning how to enhance your presentation skills from this conference recording from The ASAM 49th Annual Conference (2018). This session was made available free of charge by the ASAM Medical Education Council until 11/16/18.

    (1.5 CME) In this conference recording from the 2018 Annual Conference, you will learn about how great presentations are the result of knowledge, skills, and resources that can be applied in any type of educational setting. This workshop will feature brief didactic information to enhance knowledge with tips on how to master stage presence, gain and hold audience attention, avoid distracting mannerisms and movements, and manage difficult audiences. 

    • The "rule of three" and elements that characterize an effective presentation will be described: tell 'em what you're going to tell 'em, tell 'em, tell 'em what you told them. 
    • Effective vs. ineffective slides will be illustrated, and the incorporation of other visual resources to motivate audience learning will be highlighted. 
    • The workshop will conclude with the audience members forming dyads, wherein each member will make a brief presentation in their area of expertise to the other, who will, in turn, provide feedback. 
    • As a concluding activity, two to three volunteers will be asked to make their presentation for the entire audience, and a group discussion with feedback will be led by the audience and leaders. 

    The session incorporates humor, which not only makes the workshop a fun experience, but also eases any "jitters" and apprehension among the audience members. Residents and fellows might especially benefit from this workshop, but anyone who wants to move from making good presentations to great presentations will find this workshop to be of value.

    Marcia Jackson

    PhD

    Dr. Marcia Jackson is President of CME by Design, a consulting group that provides the full range of instructional design services in the field of continuing medical education. Dr. Jackson served as division vice president and senior advisor for education at the American College of Cardiology from 1992-2007. She is a past President of the Alliance for Continuing Medical Education, a past member of the National Task Force on CME Provider/Industry Collaboration, and current chair of the Medscape Education Advisory Board, She is a recipient of the ACCME Robert Razskowski Award and the Alliance for CME Distinguished Service Award.  She has been an ASAM consultant since 2013.

    Mike Monahan

    MEd, RN

    Mike Monahan MEd, RN  President, Healthcare Resources Associates.  Mike provides performance improvement coaching, consulting and training serving the learning and development needs of individuals, teams, and organizations primarily in healthcare.  He has developed a particular interest in the needs of leaders facing the personal and professional challenges of today’s workplace.  He has been focusing on helping teams and individuals improve measurable performance and tend to the human side of work relationships.  Mike serves as a faculty development consultant for the American College of Cardiology and Mayo.  Mike is a frequent speaker at professional conferences and has published in journals as well as co-authoring several books.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.

  • Addiction Medicine Fellowships – Welcome to the New Era of ACGME (1.5 CME)

    Product not yet rated Contains 4 Component(s), Medical Credits Offered

    Earn 1.5 AMA PRA Category 1 Credit(s)™, while learning from experts in Addiction Medicine Fellow education, presenting the latest details on what is needed to design a fellowship that can successfully join the ranks of ACCME training programs, from this conference recording from The ASAM 49th Annual Conference (2018).

    (1.5 CME) In this conference recording from the 2018 Annual Conference, you will learn how this year will mark the historic debut of the first addiction medicine fellowship programs to operate under the flag of the Accreditation Council for Graduate Medical Education (ACGME). As this workshop takes place, the inaugural period of ACGME application submissions will have just started, based on policies and an application form that were finalized only two months ago. This workshop, therefore, is a unique and timely opportunity to learn the latest details on what is needed to design a fellowship that can successfully join the ranks of ACGME training programs. To date, nearly 50 fellowships have been started under the auspices of The Addiction Medicine Foundation (TAMF), and many of those are now in the first round of applicants for ACGME accreditation. At least another 75-80 new fellowships must be developed and accredited by 2025 to meet the projected need for addiction medicine physicians. This workshop, therefore, is designed for those addiction medicine champions interested in leading new fellowships, as well as for those from existing TAMF-accredited programs that are preparing for the transition to ACGME. 

    Presenters will include four addiction medicine educators who are leaders in TAMF and the Addiction Medicine Fellowship Directors Association (AMFDA), and who are also among those now drafting ACGME applications for their own fellowships. 

    Utilizing an interactive format of case study demonstration and dialogue, they will guide participants in planning strategies to design programs that are feasible within their home institutions and responsive to ACGME requirements. Breakout sessions will then enable participants to work in small groups on an actual ACGME application form, with presenters circulating to assist them in designing fellowship rotations that will build knowledge and skills in the core competencies of addiction medicine. Participants will then reassemble for a guided discussion to identify promising approaches that emerged in the application exercise, as well as to find solutions to any potential barriers that were encountered. At the workshop’s conclusion, arrangements will be made with interested participants for ongoing technical assistance from TAMF and AMFDA.

    Lon R. Hays

    MD, MBA, DFAPA, DFASAM

    Lon Roberts Hays, M.D., M.B.A. graduated from medical school at the University of Kentucky in 1982 then pursued residency training at the University of Kentucky, which he completed in 1986. At that time he joined the faculty in the Department of Psychiatry where he has served as Chair from 1998 to 2018, and is director of the Addiction Medicine Fellowship.  In addition to being Board Certified by the American Board of Psychiatry and Neurology, Dr. Hays also is certified by the American Board of Addiction Medicine and has Added Qualifications in both Addiction Psychiatry and Geriatric Psychiatry. He completed a Certificate of Medical Management in 1998 and went on to obtain his M.B.A. from the University of Kentucky Gatton School of Business in May 2001.  Dr. Hays is a Co-investigator on numerous grants involving drugs of abuse.  He is the Director of Area V of the American Academy of Addiction Psychiatry, President of the Addiction MedicineFoundation, a Distinguished Fellow of the American Psychiatric Association, and an elected member and Fellow of the American College of Psychiatrists."

    Randall Brown

    MD, PhD, DFASAM

    Dr. Brown is on the Board of Directors of The Addiction Medicine Foundation and is President-Elect of the Addiction Medicine Fellowship Directors Association. He is Board Certified in Family Medicine and Addiction Medicine. He has been heavily involved in fellowship development at the program for which he was the founding Director at the University of Wisconsin School of Medicine and Public Health, as well as at the national level. He serves as a consulting physician in addiction medicine at UW Hospital (where he is the Director of the Center for Addictive Disorders), William S. Middleton Memorial Veterans Hospital, the UW Hospital HIV/AIDS Clinic, and at Access Community Health Centers (a network of Federally Qualified Health Centers). Dr. Brown is also the Director of the UW SMPH fourth year Clinical Addiction Elective, and the Medical Director of the Overdose Prevention Program of the AIDS Resource Center of Wisconsin. Dr. Brown holds a PhD in Population Health Sciences from the University of Wisconsin.

    Timothy K. Brennan

    MD, MPH, FASAM

    Timothy Brennan, MD, MPH, FASAM is an Addiction Medicine physician and Pediatrician. He is the Director of the Addiction Institute at Mount Sinai West and St. Luke's Hospitals in New York City and the Vice President for Medical and Academic Affairs at The Addiction Medicine Foundation. He is also the Director of the Fellowship in Addiction Medicine at the Icahn School of Medicine at Mount Sinai. He completed a Fellowship in Addiction Medicine at the Addiction Institute of New York, a Fellowship in Medical Ethics at Harvard Medical School, a Residency in Pediatrics at Weill Cornell Medical College / New York Presbyterian Hospital, and an Internship in Internal Medicine at Georgetown University Hospital. He is the Co-Editor of Essentials of Addiction Medicine and Board Certified in Addiction Medicine and Pediatrics.

    Jeanette M. Tetrault

    MD, FACP, FASAM

    Dr. Tetrault’s scholarly work focuses on care of patients with addicition and the medical co-morbidities associated with substance use, mainly HIV and Hepatitis C. She is a diplomate of the American Board of Addiction Medicine. Dr. Tetrault is a physician providing primary care and buprenorphine/naloxone treatment at the Central Medical Unit of the APT Foundation, a multi-specialty addiction treatment facility, and is an attending physician at Yale New Haven Hospital (YNHH). She is the co-director of the Addiction Recovery Clinic in the Adult Primary Care Clinic at the St. Raphael's Campus of YNHH, which serves both a clinical care and a teaching mission. She was selected as a Macy Foundation Faculty Scholar in 2017. She is the Program Director for the Yale Addiction Medicine Fellowship Program and serves on the Board of Directors for The Addiction Medicine Foundation and the Addiction Medicine Fellowship Directors Association. She is a past-president of the New England Region of SGIM and co-chair of the Alcohol, Tobacco and Other Drug Use Interest Group for SGIM.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.

  • Becoming Certified in Addiction Medicine through ABPM (1.5 CME)

    Product not yet rated Contains 4 Component(s), Medical Credits Offered

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning about Practice Pathways and Fellowships leading to board certified in Addiction Medicine, from this conference recording from The ASAM 49th Annual Conference (2018).

    (1.5 CME) In this conference recording from the 2018 Annual Conference, you will discover that in the spring of 2017, ABPM offered physicians who are certified by a Member Board of the American Board of Medical Specialties (ABMS) the opportunity to apply and become certified in the subspecialty of Addiction Medicine. Marie A. Krousel-Wood, MD, MPH, ABPM Board Chair and Michael Weaver, MD, FASAM, Addiction Medicine Subboard Chair, will review the requirements and various pathways, i.e., Practice Pathway and Fellowship, available for physicians to apply for eligibility to sit for the Addiction Medicine subspecialty exam. Information on the timeline for the 2018 application cycle, dates for the examination period, and fee schedule will also be made available. Ample time will be provided for questions from the attendees. 

    For more information visit the ABPM website at www.theabpm.org.

    Christopher J. Ondrula

    JD

    Christopher J. Ondrula, is the Executive Director of the American Board of Preventative Medicine (ABMS).  Prior to joining ABMS in 2015, Mr. Ondrula served as the Chief Executive Officer and Director at Heartland Food Corporation, and the former Chief Operating Officer and General Counsel for Spence Group Services.

    A graduate of Miami University in Oxford, Ohio, Mr. Ondrula received his Juris Doctorate from Valparaiso University School of Law. Initially practicing in Chicago area law firms where his practice
    focused on the defense of medical malpractice claims and product liability litigation, he later joined the Arena Football League as its Assistant General Counsel.

    Michael F. Weaver

    MD, DFASAM

    Dr. Michael Weaver is Professor of Psychiatry and Medical Director of the Center for Neurobehavioral Research on Addiction at The University of Texas McGovern Medical School at Houston. He completed a Residency in Internal Medicine and a Clinical Research Fellowship in Addiction Medicine at Virginia Commonwealth University. He is involved in patient care, medical education, and research. Dr. Weaver has multiple publications in the field of addiction medicine. He treats patients at the Innovations Addiction Treatment Clinic at the Texas Medical Center in Houston, which provides medication-assisted treatment. He is the Sub-Board Chair for Addiction Medicine for the American Board of Preventive Medicine.  He is a member of the ASAM Publications Council and on the Editorial Board for the Journal of Addiction Medicine.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.

  • Drug Testing: Principles and Biological Matrices in Addiction Treatment Webinar (1 CME)

    Product not yet rated Contains 4 Component(s), Medical Credits Offered

    This webinar will help build knowledge of The ASAM Appropriate Use of Drug Testing in Clinical Addiction Medicine document.

    This webinar will help build knowledge of The ASAM Appropriate Use of Drug Testing in Clinical Addiction Medicine document. The consensus document guides provider decisions about drug testing, as no universal standard exists today. It will also allow patients and their families, healthcare administrators, and payers determine clearly what is appropriate practice and what is considered outside the realm of appropriate practice in regards to drug testing in clinical addiction medicine. 

    Michael M. Miller

    MD, LFAPA, DFASAM

    Michael M. Miller, MD, DFASAM, LFAPA, is the medical director of the Herrington Recovery Center at Rogers Memorial Hospital in Oconomowoc, Wisconsin. He is a board-certified general psychiatrist and addiction psychiatrist. Dr. Miller has practiced addiction medicine for more than 30 years and is certified in addiction medicine by the American Board of Addiction Medicine. He is a Life Fellow of the American Psychiatric Association (APA) and a Distinguished Fellow of the American Society of Addiction Medicine (ASAM). Dr. Miller is also an at-large director of the American Board of Addiction Medicine (ABAM) and The ABAM Foundation, as well as a past president of ASAM. Dr. Miller has served on many task forces and councils of ASAM and the Wisconsin Medical Society (WMS), was chair of the WMS Commission on Addictive Diseases, and is current Speaker of the WMS House of Delegates and a member of the Society's Board of Directors. He serves as a faculty member for the Addiction Psychiatry Fellowship and the Addiction Medicine Fellowship at the University of Wisconsin School of Medicine and Public Health, where he is a Clinical Adjunct Professor. He also is an assistant clinical professor in the Department of Psychiatry and Behavioral Medicine at the Medical College of Wisconsin. Dr. Miller was named the national physician Clinician of the Year by Addiction Professional magazine in 2011. He was the recipient of The ASAM Award in 2013.. Through 2015, he chaired the Steering Committee of ASAM's Practice Improvement and Performance Measurement Action Group. In June 2014, Dr. Miller was elected by the AMA House of Delegates to a four year term on the AMA Council on Science and Public Health.

    Learning Objectives: 
    -Describe the principles of drug testing in the assessment and monitoring of patients with, or at risk for, addiction 
    -Discuss the benefits and liabilities of the different biological matrices relative to their roles in drug testing 
    -Highlight the consensus document's recommendations and discuss their use in clinical practice

    ACCME Accreditation Statement
    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement
    The American Society of Addiction Medicine designates this enduring material for a maximum of AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Speaker Disclosure

    Name: Michael M. Miller, MD, DFASAM

    Nature of Relevant Financial Relationship

    Category

    Organization

    Type of Relationship

    Consultant

    World Meds

    Modest ($10,000 or less)

    Consultant

    BDSI

    Modest ($10,000 or less)

    Consultant

    Braeburn

    Modest ($10,000 or less)

    Consultant

    Purdue Pharma

    Modest ($10,000 or less)

    Consultant

    WPS

    Modest ($10,000 or less)

    Speaker/Speaker’s Bureau

    BDSI

    Modest ($10,000 or less)


    ASAM CME Committee and Reviewers Disclosure Listing

    NameCommercial InterestWhat was received?For what role?
    Catherine Friedman, MD, FAPA, FASAM, ChairNone  
    Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRO
    None   
    Noel Ilogu, MD, MRCP, DFASAMNone  
    Hebert L. Malinoff, MD, FACP, DFASAMNone  
    Edwin A. Salsitz, MD, DFASAMNone  
    John C. Tanner, DO, DABAM, DFASAM, CCFC, MROIndivior

    BDSI

    Honorarium

    Honorarium

    Speaker

    Consultant/Speaker

  • Drug Testing: Special Populations and Additional Considerations in Addiction Treatment Webinar (1 CME)

    Product not yet rated Contains 4 Component(s), Medical Credits Offered

    This webinar will help to build knowledge of The ASAM Appropriate Use of Drug Testing in Clinical Addiction Medicine document. The development of the document guides provider decisions about drug testing, as no universal standard exists today.

    This webinar will help to build knowledge of The ASAM Appropriate Use of Drug Testing in Clinical Addiction Medicine document. The development of the document guides provider decisions about drug testing, as no universal standard exists today. It will also allow patients and their families, healthcare administrators, and payers determine clearly what is appropriate practice and what is considered outside the realm of appropriate practice in regards to drug testing in clinical addiction medicine. 

    JoAn Laes

    MD

    JoAn Laes, MD, Attending Physician, Division of Addiction Medicine, Hennepin County Medical Center, Minneapolis, MN; Core Medical Toxicology Faculty, Minnesota Poison Control System, Minneapolis, MN; Medical Director, Mission Detox Center, Plymouth, MN and 1800 Detox, Minneapolis, MN, ASAM Medical Toxicology workgroup Chair.Dr. Laes' practice is focused on inpatient addiction medicine and toxicology consultation and outpatient treatment of opioid and other substance use disorders. She is board certified in Internal Medicine, Addiction Medicine, and Medical Toxicology. She completed internal medicine residency at Hennepin County Medical Center and medical toxicology fellowship at Regions Hospital in St. Paul, Minnesota.

    ACCME Accreditation Statement
    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement
    The American Society of Addiction Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Learning Objectives

    • Identify the unique considerations in drug testing for special populations including adolescents and pregnant women. 
    • Summarize the consensus document's recommendations for drug testing for special populations and discuss how they should be used in practice.
    • Analyze the importance of practitioner documentation, confidentiality, language and attitude in addiction treatment.
    • Determine how to appropriately conduct drug testing on-site and/or choose a qualified laboratory.
  • Drug Testing: Process and Settings in Addiction Treatment Webinar (1 CME)

    Product not yet rated Contains 4 Component(s), Medical Credits Offered

    This webinar will help build knowledge of the process and settings of drug testing in addiction treatment, as stated in The ASAM Appropriate Use of Drug Testing in Clinical Addiction Medicine document.

    image


    This webinar will help build knowledge of the process and settings of drug testing in addiction treatment, as stated in The ASAM Appropriate Use of Drug Testing in Clinical Addiction Medicine document. It will allow physicians to determine clearly how to choose and schedule a test, and respond to test results. It will also allow physicians to recognize the specific guidance warranted by different settings and levels of care including early intervention, outpatient services, intensive outpatient/partial hospitalization services, residential/inpatient care, medically management intensive inpatient services, and opioid treatment services. This webinar is intended for addiction specialists and all providers utilizing drug testing in the context of the identification, diagnosis, treatment, and monitoring of patients with, or at risk for, addiction. It will also be useful for physicians and other providers concerned about the possibility of addiction in their patient population. 

    Ken Freedman

    MD, MS, MBA, DFASAM

    Since 2009, Dr. Freedman has worked as the Chief Medical Officer of Lemuel Shattuck Hospital in Boston; a facility that cares for many patients with substance use disorder, previously serving as Chief of Medicine. In addition, he is also a Clinical Professor of Medicine at Tufts University School of Medicine and Adjunct Clinical Associate Professor of Psychiatry at the University of Massachusetts Medical School. Dr. Freedman is board-certified in addiction medicine, internal medicine, and gastroenterology, and a member of the AMA, ACP, and AGA. He has been a member of ASAM since 1997.

    Over the past 20 years, Dr. Freedman has used his wide range of clinical and managerial skills to serve the needs of behavioral health and substance use patients. He teaches clinicians on the medically appropriate and humane treatment of pain disorders. Dr. Freedman’s professional commitment is to help move health care delivery towards the integration of medical care and substance use treatment in respectful and innovative ways. 

    ACCME Accreditation Statement
    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


    AMA Credit Designation Statement
    The American Society of Addiction Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Learning Objectives 
    1. Identify the fundamental components of the process of drug testing in addiction treatment. 
    2. Determine how to appropriately select the type of test for each patient, and how to respond to various test results. 
    3. Analyze the importance of and guidance around test scheduling and frequency. 
    4. Recognize the specific guidance warranted by drug testing in different settings and levels of care. 

  • The ASAM Review Course in Addiction Medicine 2017 (20.5 CME)

    Contains 25 Product(s)

    The ASAM Review Course in Addiction Medicine is widely recognized as the essential primer for physicians and clinicians preparing for a career in addiction medicine, as well as for primary care providers who wish to increase their skills in identifying and managing patients whose medical problems are caused or exacerbated by substance use disorders.

    Overview

    The ASAM Review Course in Addiction Medicine is widely recognized as the essential primer for physicians and clinicians preparing for a career in addiction medicine, as well as for primary care providers who wish to increase their skills in identifying and managing patients whose medical problems are caused or exacerbated by substance use disorders.

    The course offers two and a half days of sessions which are mapped to the addiction medicine exam blueprint of topics for the exam and features an outstanding faculty. Over 800 professionals attend this popular course each time it is offered. ASAM’s Review Course has had a major impact on advancing a common base of scientific knowledge among physicians and other healthcare professionals.

    Learning Objectives:

    Upon completion, participants should be able to:

    • Demonstrate practical knowledge on the neurobiology of addiction and articulate its activity in terms useful in a clinical setting
    • Describe the effects of alcohol, tobacco and other drugs in both tolerant and non-tolerant individuals
    • Describe the process for diagnosing addiction and differentiating the symptoms of addiction from those of other medical or psychiatric disorders
    • Explain the various pharmacologic and psychosocial treatments for addictive disorders and describe the factors that should be considered in selecting a treatment modality to match the needs of a specific patient
    • Describe the precipitants of relapse and current evidence-based practices to prevent and manage relapse


    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

     

    The ASAM CME Committee and Reviewers Disclosure Listing

    Name

    Commercial Interest

    What was received?

    For what role?

    Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRO, Chair

    None

     

     

    Catherine Friedman, MD

    Vice Chair

    None

     

      

    Noel Ilogu, MD, MRCP, DFASAM

    None

     

     

    Hebert L. Malinoff, MD, FACP, DFASAM

    None

     

     

    Edwin A. Salsitz, MD, DFASAM

    None

     

     

    John C. Tanner, DO, DABAM, DFASAM, CCFC, MRO

    Indivior

    BDSI

    Honorarium

    Honorarium

    Speaker

    Consultant/Speaker

     

    The ASAM Review Course Program Planning Committee Disclosure Listing

    Name

    Commercial Interest

    What was received?

    For what role?

    Petros Levounis, MD, MD, DFASAM

    None

     

     

    Abigail Herron, DO, DFASAM, FAPA

    None

     

     

    Timothy K. Brennan, MD, MPH, FASAM

    None

     

     

    David Galbis-Reig, MD, DFASAM

    Abbot Pharmaceuticals

     

    AbbVie

     

     

    Cortex Pharmaceuticals

     

    GW Pharmaceuticals

     

    Hospira

     

     

    Pfizer, INC

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

    Stock Options

     

     

    Stock Options

    (spouse)

     

    Stock Owned through IRA Rollover Account

    Stock Owned through IRA Rollover Account

    Stock Options

    (Spouse)

     

    Bonds in IRA

    Carla Marienfield, MD

    None

     

     

    Ricardo Restrepo, MD, MPH

    None

     

     

    Edwin A. Salsitz, MD, DFASAM

    None

     

     

    Erin Zerbo, MD

    None

     

     

     

    The ASAM Review Course Faculty Member Disclosure Listing

    Name

    Commercial Interest

    What was received?

    For what role?

    Petros Levounis, MD, MD, DFASAM

    None

     

     

    Abigail Herron, DO, DFASAM, FAPA

    None

     

     

    Timothy K. Brennan, MD, MPH, FASAM

    None

     

     

    Jeffrey DeVido, MD, MTS

    Philip Morris

     

     

    Altria

    Ownership Interest

     

    Ownership Interest

    Equity Shareholder

     

    Equity Shareholder

    Paul H. Earley, MD, DFASAM

    Alkermes

     

    Georgia PHP, INC

     

    Earley Counsultancy, LLC

     

    DynamiCare Health, INC

    Honoraria

     

    Salary

     

     

    Salary

     

     

     

    Salary

    Speaker

     

    Medical Director

     

     

    Principal

     

     

     

    Speaker

    James W. Finch, MD, DFASAM

    Orexo Pharmaceuticals

     

    Indivior Pharmaceuticals

    Honoraria

     

     

    Honoraria

    Speaker

     

     

    Speaker

    Marc Fishman, MD, DFASAM

    Alkermes

     

     

    US WorldMeds

     

     

     

     

    MediaRez

    Salary

     

     

    Salary

     

     

     

     

    Research Funding

    Consultant; Advisory Board

     

    Consultant; Advisory Board; Principal Research Investigator

     

    Principal Research Investigator

    David Galbis-Reig, MD, DFASAM

    Abbot Pharmaceuticals

     

    AbbVie

     

     

    Cortex Pharmaceuticals

    GW Pharmaceuticals

     

    Hospira

     

     

    Pfizer, Inc

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

    Stock Options

     

     

    Stock Options

    (spouse)

    Stock Owned through IRA Rollover Account

    Stock Owned through IRA

     

    Rollover Account

    Stock Options

    (Spouse)

    Bonds in IRA

    Leslie Hayes, MD

    None

     

     

    Carla Marienfield, MD

    None

     

     

    Ricardo Restrepo, MD, MPH

    None

     

     

    Richard Ries, MD, DFASAM

    None

     

     

    Edwin A. Salsitz, MD, DFASAM

    None

     

     

    Sharon Stancliff, MD

    None

     

     

    Timothy J. Wiegand, MD, FACMT, FAACT, FASAM

    None

     

     

    Erin Zerbo, MD

    None

     

     

    ACCME Accreditation Statement:

    The American Society of Addiction Medicine is accredited by the Accreditation Council for
    Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement:

    The American Society of Addiction Medicine designates this live activity for a maximum of 20.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    American Academy of Family Physicians: 

    This Live activity, The 2017 ASAM Review Course in Addiction Medicine & Pre-Courses, with a beginning date of 07/26/2017, has been reviewed and is acceptable for up to 27.50 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABAM Transitional Maintenance of Certification Program (Tmoc)

    This course has been approved by The American Board of Addiction Medicine (ABAM).  Physicians enrolled in the Transitional Maintenance of Certification (Tmoc) Program can apply a maximum of 20.5 AMA PRA Category 1 Credits

    Upon completion, participants should be able to:

    • Demonstrate practical knowledge on the neurobiology of addiction and articulate its activity in terms useful in a clinical setting
    • Describe the effects of alcohol, tobacco and other drugs in both tolerant and non-tolerant individuals
    • Describe the process for diagnosing addiction and differentiating the symptoms of addiction from those of other medical or psychiatric disorders
    • Explain the various pharmacologic and psychosocial treatments for addictive disorders and describe the factors that should be considered in selecting a treatment modality to match the needs of a specific patient
    • Describe the precipitants of relapse and current evidence-based practices to prevent and manage relapse

    The ASAM Review Course in Addiction Medicine provides an up-to-date review of the core content of addiction medicine for:

    • Physicians preparing for the ABPM Board Certification/Recertification Examination in addiction medicine
    • Addiction specialists seeking a "refresher" course that incorporates recent developments in addiction science and practice
    • Non-specialist physicians and other healthcare professionals needing the knowledge to identify and manage problems related to substance use disorders for their patients